Nanoparticles for protein drug delivery
View Patent ↗The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one antibiotics or equivalent bioactive agent characterized with a positive surface charge and their enhanced permeability in oral drug delivery.
1. A pharmaceutical composition of nanoparticles, said nanoparticles consisting of a positively charged chitosan, a negatively charged substrate, optionally a zero-charge compound, and a vaccine.
2. The pharmaceutical composition of claim 1 , wherein said nanoparticles have a mean particle size between about 50 and 400 nanometers.
3. The pharmaceutical composition of claim 1 , wherein said chitosan is N-trimethyl chitosan, EDTA-chitosan, low molecular weight chitosan, chitosan derivatives, or combinations thereof.
4. The pharmaceutical composition of claim 1 , wherein said nanoparticles are formed via a simple and mild ionic-gelation process.
5. The pharmaceutical composition of claim 1 , wherein said nanoparticles are formulated into a tablet or pill configuration.
6. The pharmaceutical composition of claim 5 , wherein said tablet or pill is treated with an enteric coating.
7. The pharmaceutical composition of claim 1 , wherein said nanoparticles are encapsulated in a capsule.
8. The pharmaceutical composition of claim 7 , wherein said capsule further comprises a pharmaceutically acceptable carrier, diluent, or excipient.
9. The pharmaceutical composition of claim 8 , wherein said excipient further comprises at least a solubilizer, bubbling agent, or emulsifier.
10. The pharmaceutical composition of claim 7 , wherein said capsule is treated with an enteric coating.
11. The pharmaceutical composition of claim 7 , wherein said capsule further comprises at least one permeation enhancer.
12. The pharmaceutical composition of claim 11 , wherein said permeation enhancer is selected from the group consisting of Ca 2+ chelators, bile salts, anionic surfactants, medium-chain fatty acids, phosphate esters, chitosan, and chitosan derivatives.
13. The pharmaceutical composition of claim 1 , wherein said nanoparticles are administered to an animal subject via oral administration.
14. The pharmaceutical composition of claim 1 , wherein said nanoparticles are administered to an animal subject via an intravenous route, subcutaneous injection route, intramuscular route, buccal route, intranasal route, or parenteral route.
15. The pharmaceutical composition of claim 1 , wherein said substrate is γ-PGA, α-PGA, water-soluble salts of PGA, metal salts of PGA, glycosaminoglycans, derivatives of PGA, or combinations thereof.
16. The pharmaceutical composition of claim 1 , wherein said nanoparticles are freeze-dried, thereby said nanoparticles being in a powder form.
17. The pharmaceutical composition of claim 1 , wherein said nanoparticles are mixed with trehalose and then freeze-dried, thereby said nanoparticles being in a powder form.
18. The pharmaceutical composition of claim 1 , wherein said vaccine is for prophylactic or therapeutic effects.
19. The pharmaceutical composition of claim 1 , wherein said zero-charge compound is a permeation enhancer.
20. The pharmaceutical composition of claim 1 , wherein said nanoparticles are suspended in solution for parenteral administration.